Tuesday, an analyst from Truist Securities increased the price target for Procept BioRobotics Corp (NASDAQ:PRCT) shares to $95.00, up from the previous $74.00, while reiterating a Buy rating on the stock.
The adjustment comes in light of the company's next-generation HYDROS system, which is expected to contribute to revenue momentum and drive further adoption in the treatment of benign prostatic hyperplasia (BPH), a market that remains under penetrated. Additionally, there is potential for expansion into the cancer treatment market.
The analyst expressed optimism about the future revenue prospects of Procept BioRobotics, particularly with the introduction of the HYDROS system, which was announced on August 21. The system is anticipated to be a significant driver of revenue growth heading into 2025 and beyond.
The analyst indicated that more detailed projections would be provided after management offers concrete guidance, likely during the third-quarter earnings call.
The analyst's report included hypothetical revenue upside analyses, which suggest that there could be a 10-11% or more increase in revenue compared to the 2025-2026 estimates. This projection is based on assumptions about the average selling price (ASP) of the HYDROS system and the rate at which existing systems are upgraded.
Procept BioRobotics is known for its innovative approach to the treatment of BPH, a condition that affects a large portion of the male population. The company's technology offers a minimally invasive option to patients, which is a key factor in its growing adoption.
The optimism from Truist Securities reflects confidence in Procept BioRobotics' ability to capitalize on new market opportunities and enhance its product offerings. Investors and stakeholders in the medical technology sector will be closely monitoring the company's performance as it aims to expand its reach and impact in the coming years.
In other recent news, Procept BioRobotics has been the center of attention following the FDA clearance for its Hydros robotic system. This advancement, equipped with AI-driven treatment planning and advanced imaging, is expected to enhance efficiency and overall clinical outcomes.
The system is set to be launched immediately, with availability to hospitals throughout the United States. Procept BioRobotics has also confirmed its 2024 financial guidance, which anticipates a significant 61% increase in total earnings for its second quarter of 2024, reaching $53.4 million.
Analysts from BofA Securities, TD Cowen, and Truist Securities have maintained a Buy rating on the stock and increased the price target, reflecting confidence in Procept BioRobotics' growth trajectory. This confidence is largely underpinned by the launch of the Hydros robotic system and the potential it holds for expanding the company's market presence.
However, it's worth mentioning that despite the strong earnings, the company reported a net loss of $25.6 million for the quarter. Nonetheless, Procept BioRobotics remains optimistic about its future financial outlook and continues to make strides in product advancements and robust financial growth.
InvestingPro Insights
As Procept BioRobotics Corp (NASDAQ:PRCT) gears up for the anticipated revenue growth from its next-generation HYDROS system, recent InvestingPro data and tips offer a deeper dive into the company's financial health and market performance. With a market capitalization of $4.1 billion, Procept BioRobotics is trading at a high Price / Book multiple of 16.29, reflecting a premium valuation by the market. The company's revenue growth has been impressive, with a 73.74% increase over the last twelve months as of Q2 2024. This growth is complemented by a significant 61.03% price uptick over the last six months, indicating strong investor confidence and market momentum.
However, InvestingPro Tips suggest that analysts are cautious about the company's short-term profitability, as they do not anticipate Procept BioRobotics will be profitable this year. Despite this, two analysts have revised their earnings upwards for the upcoming period, suggesting that there may be underlying factors that could lead to positive surprises. Additionally, the company's liquid assets exceed its short-term obligations, providing a buffer for operational flexibility. It's worth noting that Procept BioRobotics does not pay a dividend to shareholders, which is typical for companies focused on growth and reinvestment.
For investors seeking more comprehensive analysis, there are additional InvestingPro Tips available at: https://www.investing.com/pro/PRCT. These insights can provide valuable context for the company's strategic moves, such as the expansion into the cancer treatment market and the impact of the HYDROS system on future revenues.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.